Shaheed Zulfiqar Ali Bhutto Institute of Science and Technology

Can Digital Finance Drive Green Growth and Sustainable Development? Evidence From 118 Countries Across Development Status and Crisis Contexts

ABSTRACT This study investigates whether and under what conditions digital finance advances green growth (GG) and broader sustainable development (SD) objectives in a financially volatile, climate‐constrained, and developmentally unequal world. Using annual data for 118 developed...

Real-world safety and effectiveness of empagliflozin (Diampa®) alone or in combination with metformin (Diampa-M®) in patients with type 2 diabetes mellitus in Pakistan: a multicenter observational study

Abstract Background Type 2 diabetes mellitus (T2DM) is a growing public health challenge in Pakistan, where poor glycemic control is common. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, such as empagliflozin, have shown glycemic, cardiovascular, and renal benefits in contr...

Financial inclusion and multidimensional poverty alleviation: the moderating role of governance efficiency in Asian countries

<title>Abstract</title> Persistent multidimensional poverty across Asia reflects systemic inequalities in economic participation, where financial exclusion exacerbates deprivation in health, education, and living standards. While financial inclusion is widely advocated for povert...

Authenticity over automation: how AI-mediated sustainability communication shapes trust and green purchase intention

Purpose Drawing on signalling theory and trust theory, this research aims to explore how consumers’ perceptions of AI involvement in sustainability communication shape perceived authenticity, green brand trust and green purchase intention. It also investigates whether perceived g...

Blinatumomab versus chemotherapy in pediatric B-ALL: A meta-analysis of randomized trials in relapsed and high-risk frontline disease

BACKGROUND: B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric cancer, comprising almost 25 % of childhood malignancies. Despite advances in chemotherapy, relapse remains a major cause of treatment failure, particularly in high-risk patients. Blinatumomab, a...